Capital Expenditures for AbbVie (ABBV)
According to AbbVie's latest reported financial statements, the company's current capital expenditures (TTM) is $1.34B USD. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
ABBV
Currently viewingCapital ExpendituresSwitch metric
Latest period
$1.34B
YoY change
+24.6%
5Y CAGR
+8.8%
Peak year (2025)
$1.21B
Cumulative capital expenditures
$10.53B
CapEx history chart for AbbVie (ABBV) from 2009 to 2025
CapEx history table for AbbVie (ABBV) from 2009 to 2025
| Fiscal year | Period ended | Reported | Capital Expenditures | YoY |
|---|---|---|---|---|
| 2025 | $1.21B | +24.6% | ||
| 2024 | $974.00M | +25.4% | ||
| 2023 | $777.00M | +11.8% | ||
| 2022 | $695.00M | -11.7% | ||
| 2021 | $787.00M | -1.4% | ||
| 2020 | $798.00M | +44.6% | ||
| 2019 | $552.00M | -13.5% | ||
| 2018 | $638.00M | +20.6% | ||
| 2017 | $529.00M | +10.4% | ||
| 2016 | $479.00M | -10.0% | ||
| 2015 | $532.00M | -13.1% | ||
| 2014 | $612.00M | +24.6% | ||
| 2013 | $491.00M | +47.4% | ||
| 2012 | $333.00M | -6.3% | ||
| 2011 | $355.51M | -20.6% | ||
| 2010 | $448.00M | +43.3% | ||
| 2009 | $312.56M | — |
CapEx values are taken from AbbVie's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
AbbVie (ABBV) most recent annual capital expenditures stands at $1.21B (2025) – grew 24.6% year-over-year.
Through 2020–2025 (5 years), AbbVie capital expenditures delivered a +8.8% annualised rate; sustaining 3 straight years of year-over-year growth.
2025 marks the peak capital expenditures at $1.21B, with the historical low of $312.56M recorded in 2009.
Among 8 Healthcare peers, AbbVie (ABBV) ranks 9th; the peer median for capital expenditures is $3.87B.
AbbVie Capital Expenditures by Year
AbbVie Capital Expenditures 2025: $1.21B
AbbVie capital expenditures in 2025 was $1.21B, grew 24.6% from 2024. This figure represents the highest annual value in the available history.
AbbVie Capital Expenditures 2024: $974.00M
AbbVie capital expenditures in 2024 was $974.00M, grew 25.4% from 2023.
AbbVie Capital Expenditures 2023: $777.00M
AbbVie capital expenditures in 2023 was $777.00M, grew 11.8% from 2022.
AbbVie Capital Expenditures 2022: $695.00M
AbbVie capital expenditures in 2022 was $695.00M, declined 11.7% below 2021.
AbbVie Capital Expenditures 2021: $787.00M
AbbVie capital expenditures in 2021 was $787.00M.
See more financial history for AbbVie (ABBV).
Sector peers — CapEx
Companies in the same sector as AbbVie, ranked by their latest capital expenditures.
| Company | Capital Expenditures | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $90.11B | Healthcare |
| Eli Lilly and Company (LLY) | $7.84B | Healthcare |
| Johnson & Johnson (JNJ) | $4.83B | Healthcare |
| Merck & Co., Inc. (MRK) | $4.11B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $3.62B | Healthcare |
| AstraZeneca PLC (AZN) | $2.81B | Healthcare |
| Amgen Inc. (AMGN) | $1.86B | Healthcare |
| Thermo Fisher Scientific Inc. (TMO) | $1.52B | Healthcare |
Frequently asked questions
What is AbbVie's capital expenditures?
- Latest reported capital expenditures for AbbVie (ABBV) is $1.34B (period ending December 31, 2025).
How has AbbVie capital expenditures changed year-over-year?
- AbbVie (ABBV) capital expenditures changed +24.6% year-over-year on the latest annual filing.
What is the long-term growth rate of AbbVie capital expenditures?
- AbbVie (ABBV) capital expenditures compound annual growth rate is +8.8% over the most recent 5 years available.
When did AbbVie capital expenditures hit its highest annual value?
- AbbVie capital expenditures reached its highest annual value of $1.21B in 2025.
What was AbbVie capital expenditures in 2024?
- AbbVie (ABBV) capital expenditures in 2024 was $974.00M.
What was AbbVie capital expenditures in 2025?
- AbbVie (ABBV) capital expenditures in 2025 was $1.21B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
ABBV Overview
Company profile, financial tools, and key metrics
ABBV Revenue Counter
Earns $1,939 every second. See per minute, hour, and day.
ABBV Earnings Counter
Earns $134.01 per second net profit. See per minute, hour, and day.
ABBV Economic Scale
Exceeds Bolivia's GDP. Compare with world economies.
ABBV What If Invested
What if you had invested $1,000? See historical returns from any date.
ABBV How It Makes Money
Discover visual breakdown of $61.16B in revenue — where it comes from and where it goes.
ABBV Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ABBV Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ABBV Daily Price Character
Steady · 53.5% historical win rate (green days). Streaks & record days.
ABBV Buybacks
0.24% TTM buyback yield. Shareholder yield & SBC comparison.
ABBV Dividend Profile
Yield: 3.31%. Safety: 6/8. See full history.
ABBV Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
ABBV Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.